Giuseppe Schepisi

15PUBLICATIONS
32CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (15)

|Jul 08, 2026
Ineffectiveness of immune checkpoint inhibitors in prostate cancer: is it just a question of '-mabs'?

|Mar 13, 2026
Lipidomic profiling in metastatic prostate cancer captures tumor metabolic rewiring and its modulation by androgen receptor-targeting therapy.

Sara Bleve, Francesco Ravera, Silvia Rodrigues

|Feb 19, 2026
Impact of Circulating Tumor DNA and Copy-Number Alterations on Clinical Outcome in Relapsed/Refractory Germ Cell Tumors Treated With Salvage High-Dose Chemotherapy.

Milena Urbini, Thomas F Eleveld, Maurizio Polano

|Feb 12, 2024
Initial management approach for localized/locally advanced disease is critical to guide metastatic castration-resistant prostate cancer care.

Vincenza Conteduca, Piergiorgio Di Tullio, Rossana Allamprese

|Dec 09, 2023
Biomarkers for Salvage Therapy in Testicular Germ Cell Tumors.

Milena Urbini, Sara Bleve, Giuseppe Schepisi

|Jul 13, 2023
Immunogenomic profiles associated with response to life-prolonging agents in prostate cancer.

Vincenza Conteduca, Nicole Brighi, Giuseppe Schepisi

Pageof 3

Frequent Collaborators

9 joint publications

Ugo De Giorgi

7 joint publications

Vincenza Conteduca

5 joint publications

Giorgia Gurioli

4 joint publications

Milena Urbini